These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

482 related items for PubMed ID: 26332121

  • 1. Human Monoclonal Antibody Targeting the Heparan Sulfate Chains of Glypican-3 Inhibits HGF-Mediated Migration and Motility of Hepatocellular Carcinoma Cells.
    Gao W, Kim H, Ho M.
    PLoS One; 2015; 10(9):e0137664. PubMed ID: 26332121
    [Abstract] [Full Text] [Related]

  • 2. Inactivation of Wnt signaling by a human antibody that recognizes the heparan sulfate chains of glypican-3 for liver cancer therapy.
    Gao W, Kim H, Feng M, Phung Y, Xavier CP, Rubin JS, Ho M.
    Hepatology; 2014 Aug; 60(2):576-87. PubMed ID: 24492943
    [Abstract] [Full Text] [Related]

  • 3. A Frizzled-Like Cysteine-Rich Domain in Glypican-3 Mediates Wnt Binding and Regulates Hepatocellular Carcinoma Tumor Growth in Mice.
    Li N, Wei L, Liu X, Bai H, Ye Y, Li D, Li N, Baxa U, Wang Q, Lv L, Chen Y, Feng M, Lee B, Gao W, Ho M.
    Hepatology; 2019 Oct; 70(4):1231-1245. PubMed ID: 30963603
    [Abstract] [Full Text] [Related]

  • 4. The oncogenic effect of sulfatase 2 in human hepatocellular carcinoma is mediated in part by glypican 3-dependent Wnt activation.
    Lai JP, Oseini AM, Moser CD, Yu C, Elsawa SF, Hu C, Nakamura I, Han T, Aderca I, Isomoto H, Garrity-Park MM, Shire AM, Li J, Sanderson SO, Adjei AA, Fernandez-Zapico ME, Roberts LR.
    Hepatology; 2010 Nov; 52(5):1680-9. PubMed ID: 20725905
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of antiglypican-3 therapy as a promising target for amelioration of hepatic tissue damage in hepatocellular carcinoma.
    Zaghloul RA, El-Shishtawy MM, El Galil KH, Ebrahim MA, Metwaly AA, Al-Gayyar MM.
    Eur J Pharmacol; 2015 Jan 05; 746():353-62. PubMed ID: 25449037
    [Abstract] [Full Text] [Related]

  • 6. Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer.
    Fleming BD, Ho M.
    Toxins (Basel); 2016 Sep 22; 8(10):. PubMed ID: 27669301
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Glypican-3 promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells through ERK signaling pathway.
    Wu Y, Liu H, Weng H, Zhang X, Li P, Fan CL, Li B, Dong PL, Li L, Dooley S, Ding HG.
    Int J Oncol; 2015 Mar 22; 46(3):1275-85. PubMed ID: 25572615
    [Abstract] [Full Text] [Related]

  • 9. Role of Glypican-3 in the growth, migration and invasion of primary hepatocytes isolated from patients with hepatocellular carcinoma.
    Montalbano M, Rastellini C, McGuire JT, Prajapati J, Shirafkan A, Vento R, Cicalese L.
    Cell Oncol (Dordr); 2018 Apr 22; 41(2):169-184. PubMed ID: 29204978
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Glypican-3: a marker and a therapeutic target in hepatocellular carcinoma.
    Filmus J, Capurro M.
    FEBS J; 2013 May 22; 280(10):2471-6. PubMed ID: 23305321
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling.
    Capurro MI, Xiang YY, Lobe C, Filmus J.
    Cancer Res; 2005 Jul 15; 65(14):6245-54. PubMed ID: 16024626
    [Abstract] [Full Text] [Related]

  • 14. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma.
    Capurro M, Wanless IR, Sherman M, Deboer G, Shi W, Miyoshi E, Filmus J.
    Gastroenterology; 2003 Jul 15; 125(1):89-97. PubMed ID: 12851874
    [Abstract] [Full Text] [Related]

  • 15. Overexpression of GPC3 inhibits hepatocellular carcinoma cell proliferation and invasion through induction of apoptosis.
    Pan Z, Chen C, Long H, Lei C, Tang G, Li L, Feng J, Chen F.
    Mol Med Rep; 2013 Mar 15; 7(3):969-74. PubMed ID: 23338845
    [Abstract] [Full Text] [Related]

  • 16. Cellular changes resulting from forced expression of glypican-3 in hepatocellular carcinoma cells.
    Kwack MH, Choi BY, Sung YK.
    Mol Cells; 2006 Apr 30; 21(2):224-8. PubMed ID: 16682817
    [Abstract] [Full Text] [Related]

  • 17. Long noncoding RNA glypican 3 (GPC3) antisense transcript 1 promotes hepatocellular carcinoma progression via epigenetically activating GPC3.
    Zhu XT, Yuan JH, Zhu TT, Li YY, Cheng XY.
    FEBS J; 2016 Oct 30; 283(20):3739-3754. PubMed ID: 27573079
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Human hepatic myofibroblasts increase invasiveness of hepatocellular carcinoma cells: evidence for a role of hepatocyte growth factor.
    Neaud V, Faouzi S, Guirouilh J, Le Bail B, Balabaud C, Bioulac-Sage P, Rosenbaum J.
    Hepatology; 1997 Dec 30; 26(6):1458-66. PubMed ID: 9397985
    [Abstract] [Full Text] [Related]

  • 20. Anti-glypican 3 antibodies cause ADCC against human hepatocellular carcinoma cells.
    Nakano K, Orita T, Nezu J, Yoshino T, Ohizumi I, Sugimoto M, Furugaki K, Kinoshita Y, Ishiguro T, Hamakubo T, Kodama T, Aburatani H, Yamada-Okabe H, Tsuchiya M.
    Biochem Biophys Res Commun; 2009 Jan 09; 378(2):279-84. PubMed ID: 19022220
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.